Effects of Metformin Monotherapy on Metabolic Parameters in Japanese Patients With Type 2 Diabetes

Hisayuki Katsuyama, Hidekatsu Yanai

Abstract


Background: Although metformin is widely used as the foundation therapy for patients with type 2 diabetes, effects of metformin monotherapy on metabolic parameters have not been sufficiently elucidated.

Methods: We retrospectively picked up type 2 diabetic patients who had been treated by the first metformin monotherapy for more than 3 months, at National Center for Global Health and Medicine between January 2015 and October 2018.

Results: Twenty-two patients were eligible. Systolic blood pressure, plasma glucose, HbA1c, low-density lipoprotein-cholesterol (LDL-C), aspartate transaminase (AST), and alanine aminotransferase (ALT) were significantly reduced by the 3-month metformin monotherapy. Further, we divided subjects into two groups with body mass index (BMI) of 25 or more and less than 25, and compared changes in metabolic parameter due to metformin monotherapy between BMI ? 25 and BMI < 25 groups. HbA1c and LDL-C were significantly reduced in both groups. Body weight significantly decreased only in BMI ? 25 group, and systolic blood pressure, AST and ALT tended to decrease only in BMI ? 25 group.

Conclusions: The metformin monotherapy improved glycemic control regardless of the presence or absence of obesity. Interestingly, metformin improved body weight, blood pressure and liver function in only overweight patients with type 2 diabetes.




J Endocrinol Metab. 2019;9(1-2):18-21
doi: https://doi.org/10.14740/jem549


Keywords


Body weight; Gluconeogenesis; Metformin; Liver function; Low-density lipoprotein-cholesterol

Full Text: HTML PDF
 
Home     |     Log In     |      About     |      Search     |      Current     |      Archives     |      Submit      |     Subscribe


 

     

Aims and Scope

Current Issues

Conflict of Interest

About Publisher

Editorial Board

Archives

Copyright

Company Profile

Editorial Office

Misconduct and Retraction

Permissions

Company Registration

Contact Us

Abstracting and Indexing

ICMJE

Ownership

Instructions to Authors

Access

Declaration of Helsinki

Contact Publisher

Submission Checklist

Reprints

Terms of Use

Company Address

Submit a Manuscript

Open Access Policy

Privacy Policy

Browse Journals

Publishing Fee

Publishing Policy

Disclaimer

Recent Highlights

Peer-Review Process

Publishing Quality

Code of Ethics

Advertising Policy

Manuscript Tracking

Advanced Search

For Librarians

Careers

Publishing Process

Publication Frequency

For Reviewers

Propose a New Journal

       
       

Journal of Endocrinology and Metabolism, bimonthly, ISSN 1923-2861 (print), 1923-287X (online), published by Elmer Press Inc.        
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)


This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.jofem.org   editorial contact: editor@jofem.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.